BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Eli Lilly and Company

Eli Lilly and Company logo

Founded
1876
Patents
79
Clinical Trials
1764
Publications
102

Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Products Neurosciences products, include: Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents and adults; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder; and Symbyax, for the treatment of bipolar depression. Endocrinology products, include: Humalog, Humalog Mix 75/25, and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Actos, for the treatment of type 2 diabetes; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; and Humatrope, for the treatment of human growth hormone deficiency and idiopathic short stature.


Posts Mentioning This Company

How Pharma Reacts To Wuhan Coronavirus Outbreak

  
UPDATE April 04. 2020. The number of confirmed cases of COVID19 approaches 1M globally. Since too many drug repurposing programs and vaccine development projects have been urgently initiated, we decided to summarize them in a separate post: A Running List Of COVID-19 Treatments And Vaccines In Development With this, we …
SHARE